

Financial Tear Sheet


Corporate Profile

Amgen, the world's largest biotechnology company, uses science and innovation in an effort to dramatically improve people's lives. Amgen aspires to be the world's best human therapeutics company.

Our researchers harness the powerful tools of cellular and molecular biology and medicinal chemistry to discover, develop and commercialize naturally occurring proteins, antibodies and small molecules, with the goal of extending the reach of science to unleash the body's own powerful therapeutic responses. Amgen's research and product development programs aim to help patients in four critical areas: nephrology, hematology and oncology, bone and inflammation, neurology and endocrinology.

Stock Performance

AMGN (COMMON STOCK)	
Exchange	NASDAQ (US Dollar)
Price	\$171.56
Change (%)	▼ 2.26 (1.30%)
Volume	1,621,854
52 Week Low	\$133.64
Market Cap	\$126,165,074,400
Rolling EPS	10.53
PE Ratio	16.2925
Shares Outstanding	735,399,128



Data as of 06/23/17 12:12 p.m. ET

Recent Headlines

06/21/17

Amgen To Present New Data At 22nd Congress of the European Hematology Association

06/19/17

FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA® (denosumab) To Include Multiple Myeloma Patients

06/08/17


Amgen Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society

Upcoming Events

There are currently no events scheduled.

Analyst Estimates / Ratings

Mean Recommendation: **2.4**



EPS TREND

		Current	30 Days Ago	90 Days Ago
QTR	Jun 17	3.09	3.10	3.11
QTR	Sep 17	3.12	3.13	3.13
QTR	Dec 17	3.09	3.10	3.09
QTR	Mar 18	3.06	3.08	3.08
FY	Dec 17	12.43	12.46	12.31
FY	Dec 18	12.73	12.69	12.75

SEC Filings

FILING DATE	FORM
06/13/17	11-K
06/13/17	11-K
06/02/17	4
05/26/17	CT ORDER

Financial Reports

Q1 2017 Financial Results

Presentations

05/18/17	Investor Insights Newsletter - Q1 2017
----------	--

Data provided by Nasdaq. Minimum 15 minutes delayed.